- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02083406
Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)
Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG11 6JS
- Quotient Clinical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males, or healthy females of non-childbearing potential ie surgically sterilised or post-menopausal (amenorrhoea for at least 1 year and confirmed by a follicle stimulating hormone result of ≥25 IU/mL
- Age 18 to 55 years of age
- Body mass index of 18.0 to 30.0 kg/m2 inclusive. Total body weight >50 kg at screening
- Willing and able to communicate and participate in the whole study
- Must provide written informed consent
- Must agree to use an adequate method of contraception
- Must have liver function tests and haemoglobin within the laboratory reference range at screening and Day -1
- Must have heart trace measurements within the defined healthy limits at screening, Day -1 and pre-dose
Exclusion Criteria:
- Male subjects who have currently pregnant partners
- Evidence or history of clinically significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, haematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection
- Clinically relevant abnormalities in the heart trace including any degree of heart block, including asymptomatic bundle branch block
- Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval
- History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia
- Electrolyte disturbances, particularly hypokalemia, hypocalcaemia or hypomagnesaemia.
- Any condition that could possibly affect drug absorption, such as gastrectomy or diarrhoea
- History of post-antibiotic colitis
- History of any drug or alcohol abuse in the past 2 years prior to screening
- Subjects who have a breath carbon monoxide reading of greater than 10 ppm at screening will be excluded. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use within 90 days before screening.
- Receipt of an investigational drug or participation in another clinical research study within 90 days prior to drug administration.
- Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
- Subjects who have previously been enrolled in this study
Use of ANY prescription or non-prescription medications, vitamins, herbal supplements or dietary supplements, including protein supplements, within 14 days prior to the first dose of study drug and throughout the study, unless prior approval is granted by both the investigator and the sponsor. An exception will be made for intermittent use of paracetamol and hormone replacement therapy. Paracetamol at doses of, at most, 2 g per day or no more than 3 consecutive days or 6 non consecutive days, are allowed until 24 hours before dosing with study drug. Longer exclusion periods apply for:
- amiodarone and hydroxychloroquine (210 days)
- monoclonal antibodies/ immunoglobulins/ other therapeutic proteins and experimental drugs for which the half-life is not known to the investigator (120 days)
- experimental drugs for which half-life is known to the investigator (5 half lives plus 14 days)
- chloroquine, piperaquine phosphate and flunarizine (100 days)
- fluoxetine (75 days)
- benzodiazepines (for midazolam, lorazepam and triazolam, the exclusion period is 14 days), chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone, phenprocoumone and cytochrome P450 3A4 inducers not already mentioned, including but not restricted to, rifampin, carbamazepine, oxcarbazepine, phenytoin and St John's Wort (35 days)
- Positive hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus results
- Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
- Positive urine drug screen result at screening or admission to the clinical unit
- History of intolerance or hypersensitivity to piperaquine or any 4-aminoquinolone, or ascertained or presumptive hypersensitivity to the active principle and/or formulation ingredients; history of anaphylaxis to drugs or allergic reactions in general, that the investigator considers may affect the outcome of the study
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Presence or history of allergy requiring treatment; hayfever is allowed unless it is active
- Donation or loss of >400 mL of blood within 90 days prior to drug administration
- Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- Subjects who do not have suitable veins for multiple blood samples as assessed by the investigator at screening
- Failure to satisfy the investigator of fitness to participate for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A: OZ439 Prototype 1
800mg OZ439 prototype formulation 1 and 960mg PQP single doses
|
Other Names:
Other Names:
|
Experimental: Treatment B: OZ439 Prototype 2
800mg OZ439 prototype formulation 2 and 960mg PQP single doses
|
Other Names:
Other Names:
|
Experimental: Treatment C: OZ439 Prototype 3
800mg OZ439 prototype formulation 3 and 960mg PQP single doses
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OZ439 AUC(0-168h)
Time Frame: Up to 168 hours post-dose
|
OZ439 Area under the plasma concentration (AUC) versus time curve
|
Up to 168 hours post-dose
|
OZ439 Cmax
Time Frame: Up to 168 hours post-dose
|
OZ439 Maximum observed concentration
|
Up to 168 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Piperaquine (PQ) AUC(0-168h)
Time Frame: Up to 168h post-dose
|
PQ Area under the plasma concentration versus time curve
|
Up to 168h post-dose
|
PQ Cmax
Time Frame: Up to 168h post-dose
|
PQ Maximum observed concentration
|
Up to 168h post-dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jo Collier, MBChB FFPM, Quotient Clinical
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMV_OZ439_13_007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on 800mg OZ439 prototype formulation 1
-
Medicines for Malaria VentureSyneos Health; Nucleus Network LtdCompletedHealthy VolunteersAustralia
-
Medicines for Malaria VentureQuotient ClinicalCompleted
-
Medicines for Malaria VentureCompletedHealthy Volunteers | Malaria Falciparum | Malaria VivaxUnited States
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Janssen Research & Development, LLCCompleted
-
H. Lundbeck A/SCompleted
-
Sheffield Children's NHS Foundation TrustCompletedRheumatologic DiseaseUnited Kingdom
-
Shiphrah Biomedical Inc.University of South AustraliaTerminatedPregnancy Complications | Fetal Growth Retardation | Sleep-Disordered Breathing | Infant, Very Low Birth Weight | Stillbirth | Infant, Small for Gestational Age | Fetal Hypoxia | Infant, Low Birth WeightAustralia
-
Lyndra Inc.TerminatedHealthy | Gastric RetentionUnited Kingdom